PMID- 17803450
OWN - NLM
STAT- MEDLINE
DCOM- 20071031
LR  - 20201215
IS  - 1084-9785 (Print)
IS  - 1084-9785 (Linking)
VI  - 22
IP  - 4
DP  - 2007 Aug
TI  - GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients.
PG  - 551-5
AB  - Twenty-four (24) pretreated patients with relapsed high-risk resected The 
      American Joint Committee on Cancer (AJCC) stage IIA-IV melanoma received adjuvant 
      peptide vaccinations derived from the melanosomal antigens MelanA/MART1, MAGE-1, 
      gp100, and tyrosinase, according to patient tumor-associated human leukocyte 
      antigen (HLA) restricted antigen expression, in combination with 
      granulocyte-macrophage colony-stimulating factor (GM-CSF). Pretreatment was 
      comprised of surgery (n=23 primary tumor; n=23 metastases), local radiotherapy 
      (n=2), immunotherapy (n=23), chemotherapy (n=10), and chemoimmunotherapy (n=1), 
      respectively. All patients received peptide vaccines in an adjuvant setting. 
      Seven (7) patients were relapse free for 3+ up to 25+ months. Of the patients 
      exhibiting progressive disease (n=17), 13 patients developed metastases during 
      vaccination (9 local, 4 distant), and 4 patients developed metastases (2 local, 2 
      distant) after finishing vaccine therapy. Two (2)-year local and distant 
      metastases-free survival, 2-year distant metastases-free survival, and 2-year 
      overall survival were calculated as 8.6%, 68%, and 85%, respectively. Vaccine 
      treatment was well tolerated, with no severe side-effects. Twenty (20) of 24 
      patients developed local delayed-type hypersensitivity (DTH) reactions to 
      synthetic peptide vaccination. Transient fever (n=2) and pain in muscle/bone 
      (n=2) occurred rarely. In conclusion, antigenic peptide vaccination, combined 
      with GM-CSF, is safe and may yield clinical benefits in relapsed high-risk 
      resected melanoma patients.
FAU - Atzpodien, Jens
AU  - Atzpodien J
AD  - Fachklinik Hornheide an der Westfalische Wilhelms-Universitat Munster, Munster, 
      Germany. SekrProfAtzpodien@yahoo.de
FAU - Reitz, Martina
AU  - Reitz M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Peptide Fragments)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cancer Vaccines/adverse effects/*immunology/*therapeutic use
MH  - Female
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects/*therapeutic use
MH  - Histocompatibility Antigens/*immunology
MH  - Humans
MH  - Immunotherapy
MH  - Male
MH  - Melanoma/immunology/*pathology/*therapy
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Peptide Fragments/*immunology
MH  - Risk Factors
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2007/09/07 09:00
MHDA- 2007/11/01 09:00
CRDT- 2007/09/07 09:00
PHST- 2007/09/07 09:00 [pubmed]
PHST- 2007/11/01 09:00 [medline]
PHST- 2007/09/07 09:00 [entrez]
AID - 10.1089/cbr.2007.376 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2007 Aug;22(4):551-5. doi: 10.1089/cbr.2007.376.